Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet Study

Journal of Clinical Oncology

Volumn 27, Issue 31, 2009, Pages 5195-5201

  Cilloni, Daniela ^a   Renneville, Aline ^a   Hermitte, Fabienne ^a   Hills, Robert K ^a   Daly, Sarah ^a   Jovanovic, Jelena V ^a   Gottardi, Enrico ^a   Fava, Milena ^a   Schnittger, Susanne ^a   Weiss, Tamara ^a   Izzo, Barbara ^a   Nomdedeu, Josep ^a   Van Der Heijden, Adrian ^a   Van Der Reijden, Bert A ^a   Jansen, Joop H ^a   Van Der Velden, Vincent H J ^a   Ommen, Hans ^a   Preudhomme, Claude ^a   Saglio, Giuseppe ^a   Grimwade, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; BONE MARROW; CANCER RELAPSE; CHILD; CONTROLLED STUDY; FEMALE; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NEWBORN; PATIENT MONITORING; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE DIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; SCHOOL CHILD; WT1 GENE; DRUG EFFECT; GENE EXPRESSION; GENETICS; METHODOLOGY; MIDDLE AGED; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION; GENES, WILMS TUMOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 70449726860     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.4865     Document Type: Article

References (46)

1. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003
2. Estey E, Döhner H: Acute myeloid leukemia. Lancet 368:1894-1907, 2006
3. Mrózek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 18:115-136, 2004
4. Kottaridis PD, Gale RE, Linch DC: Flt3 mutations and leukaemia. Br J Haematol 122:523-538, 2003
5. Falini B, Mecucci C, Tiacci E, et al: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266, 2005
6. Mrózek K, Bloomfield CD: Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 169-177, 2006
7. Schlenk RF, Döhner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1909-1918, 2008
8. Lugthart S, van Drunen E, van Norden Y, et al: High EVI1 levels predict adverse outcome in acute myeloid leukemia: Prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111:4329-4337, 2008
9. Wheatley K, Burnett AK, Goldstone AH, et al: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial: United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 107:69-79, 1999
10. Freeman SD, Jovanovic JV, Grimwade D: Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 4:388-400, 2008
11. Sugiyama H: Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 73:177-187, 2001
12. Inoue K, Sugiyama H, Ogawa H, et al: WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071-3079, 1994
13. Inoue K, Ogawa H, Yamagami T, et al: Longterm follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 88:2267-2278, 1996
14. Inoue K, Ogawa H, Sonoda Y, et al: Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89:1405-1412, 1997
15. Cilloni D, Gottardi E, De Micheli D, et al: Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16:2115-2121, 2002
16. Trka J, Kalinova M, Hrusak O, et al: Real-time quantitative PCR detection of WT1 gene expression in children with AML: Prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 16:1381-1389, 2002
17. Cilloni D, Gottardi E, Fava M, et al: Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection. Blood 102:773-774, 2003
18. Weisser M, Kern W, Rauhut S, et al: Prognostic impact of RT-PCR based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19:1416-1423, 2005
19. Lapillonne H, Renneville A, Auvrignon A, et al: High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 24:1507-1515, 2006
20. Cilloni D, Messa F, Arruga F, et al: Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 93:921-924, 2008
21. Garg M, Moore H, Tobal K, et al: Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 123:49-59, 2003
22. Ogawa H, Tamaki H, Ikegame K, et al: The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101:1698-1704, 2003
23. Østergaard M, Olesen LH, Hasle H, et al: WT1 gene expression: An excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients-Results from a single-centre study. Br J Haematol 125:590-600, 2004
24. Ommen HB, Nyvold CG, Braendstrup K, et al: Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: Development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 141:782-791, 2008
25. Liu-Yin J, Sale M, Daly S, et al: Predictive value of minimal residual disease (MRD) monitoring by RQ-PCR in WT1 positive patients entered in the UK MRC AML-15 Trial. Blood 112:259, 2008 (abstr 697)
26. King-Underwood L, Pritchard-Jones K: Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 91:2961-2968, 1998
27. Summers K, Stevens J, Kakkas I, et al: Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 21:550-551, 2007
28. Virappane P, Gale R, Hills R, et al: Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 26:5429-5435, 2008
29. Paschka P, Marcucci G, Ruppert AS, et al: Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 26:4595-4602, 2008
30. Gaidzik VI, Schlenk RF, Moschny S, et al: Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia (AML): A study of the German-Austrian AML Study Group (AMLSG). Blood 113:4505-4511, 2009
31. Nyvold CG, Stentoft J, Braendstrup K, et al: Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: Biological and clinical implications. Leukemia 20:2051-2054, 2006
32. Gabert J, Beillard E, van der Velden VHJ, et al: Standardization and quality control studies of 'realtime' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17:2318-2357, 2003
33. Beillard E, Pallisgaard N, van der Velden VHJ, et al: Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): A Europe Against Cancer program. Leukemia 17:2474-2486, 2003
34. Flora R, Grimwade D: Real-time quantitative RT-PCR to detect fusion gene transcripts associated with AML. Methods Mol Med 91:151-173, 2004
35. Grimwade D, Jovanovic JV, Hills RK, et al: Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 27:3650-3658, 2009
36. Osborne D, Frost L, Tobal K, et al: Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia. Bone Marrow Transplant 36:67-70, 2005
37. Van Dijk JP, Knops GH, Van De Locht LT, et al: Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow. Br J Haematol 118:1027-1033, 2002
38. Thomas X, Raffoux E, de Botton S, et al: Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: A trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 21:453-461, 2007
39. Pautas C, Thomas X, Merabet F, et al: Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 days in AML pts aged 50 to 70 and of maintenance with interleukin 2. Final analysis of the ALFA 9801 study. Blood 110:55a, 2007 (abstr 162)
40. Büchner T, Berdel WE, Schoch C, et al: Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 24:2480-2489, 2006
41. Lo-Coco F, Cuneo A, Pane F, et al: Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. Haematologica 93:1017-1024, 2008
42. EORTC protocol AML-12/06991, http://www .eortc.be/protoc/Details.asp? Protocol=06991
43. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial - The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333, 1998
44. Stauss HJ, Thomas S, Cesco-Gaspere M, et al: WT1-specific T cell receptor gene therapy: Improving TCR function in transduced T cells. Blood Cells Mol Dis 40:113-116, 2008
45. Greiner J, Döhner H, Schmitt M: Cancer vaccines for patients with acute myeloid leukemia: Definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 91:1653-1661, 2006
46. Barragán E, Cervera J, Bolufer P, et al: Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 89:926-933, 2004